Literature DB >> 16049565

Atypical antipsychotics for mood and anxiety disorders: safe and effective adjuncts?

Pierre Blier.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16049565      PMCID： PMC1160557     

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN： 1180-4882            Impact factor:   6.186


× No keyword cloud information.
  17 in total

Review 1.  Pharmacologic treatment of posttraumatic stress disorder: a focus on antipsychotic use.

Authors:  Eileen P Ahearn; Amy Krohn; Kathryn M Connor; Jonathan R T Davidson
Journal:  Ann Clin Psychiatry       Date:  2003 Sep-Dec       Impact factor: 1.567

2.  Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding.

Authors:  A Schotte; P F Janssen; W Gommeren; W H Luyten; P Van Gompel; A S Lesage; K De Loore; J E Leysen
Journal:  Psychopharmacology (Berl)       Date:  1996-03       Impact factor: 4.530

Review 3.  Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.

Authors:  Charles L Bowden
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

4.  A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder.

Authors:  C J McDougle; C N Epperson; G H Pelton; S Wasylink; L H Price
Journal:  Arch Gen Psychiatry       Date:  2000-08

5.  A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.

Authors:  Damiaan Denys; Femke de Geus; Harold J G M van Megen; Herman G M Westenberg
Journal:  J Clin Psychiatry       Date:  2004-08       Impact factor: 4.384

6.  Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.

Authors:  Alexander Bystritsky; Deborah L Ackerman; Richard M Rosen; Tanya Vapnik; Eda Gorbis; Karron M Maidment; Sanjaya Saxena
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

7.  Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.

Authors:  Natalie Alméras; Jean-Pierre Després; Julie Villeneuve; Marie-France Demers; Marc-André Roy; Camille Cadrin; Jean-Pierre Mottard; Roch-Hugo Bouchard
Journal:  J Clin Psychiatry       Date:  2004-04       Impact factor: 4.384

8.  Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study.

Authors:  Eric Hollander; Nicolò Baldini Rossi; Erica Sood; Stefano Pallanti
Journal:  Int J Neuropsychopharmacol       Date:  2003-12       Impact factor: 5.176

9.  Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.

Authors:  Mauricio Tohen; Eduard Vieta; Joseph Calabrese; Terence A Ketter; Gary Sachs; Charles Bowden; Philip B Mitchell; Franca Centorrino; Richard Risser; Robert W Baker; Angela R Evans; Karin Beymer; Sanjay Dube; Gary D Tollefson; Alan Breier
Journal:  Arch Gen Psychiatry       Date:  2003-11

10.  A double-blind, placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive-compulsive disorder.

Authors:  Nathan A Shapira; Herbert E Ward; Miguel Mandoki; Tanya K Murphy; Mark C K Yang; Pierre Blier; Wayne K Goodman
Journal:  Biol Psychiatry       Date:  2004-03-01       Impact factor: 13.382
View more
  2 in total

1.  Buprenorphine/samidorphan combination for the adjunctive treatment of major depressive disorder: results of a phase III clinical trial (FORWARD-3).

Authors:  John M Zajecka; Arielle D Stanford; Asli Memisoglu; William F Martin; Sanjeev Pathak
Journal:  Neuropsychiatr Dis Treat       Date:  2019-04-04       Impact factor: 2.570

Review 2.  Mechanism of Action of Atypical Antipsychotic Drugs in Mood Disorders.

Authors:  Daniil Grinchii; Eliyahu Dremencov
Journal:  Int J Mol Sci       Date:  2020-12-15       Impact factor: 6.208
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.